Disclosure. Objectives
|
|
- Robyn Gray
- 6 years ago
- Views:
Transcription
1 Charles A. Leath, III, MD, MSPH Associate Professor University of Alabama at Birmingham Disclosure I have no potential financial or other conflicts of interest. The view(s) expressed herein are those of the author and do not reflect the official policy or position ii of University i of Alabama at Birmingham. Objectives Review and discuss the rationale for consideration of salpingectomy at time of hysterectomy and in place of tubal ligation Examine the evidence and support for salpingectomy as a preventative strategy Convince you that anything that Jacob Estes has to say should be ignored 1
2 Patient populations in front line Objectives Review and discuss the rationale for consideration of salpingectomy at time of hysterectomy and in place of tubal ligation Examine the evidence and support for salpingectomy as a preventative strategy Convince you that anything that Jacob Estes has to say should be ignored The Magnitude of the Problem Ovarian Cancer Statistics 2015 New Cases 21,290 (21,980 in 2014) Deaths 14,180 (14,270 in 2014) Primarily advanced stage disease at diagnosis Limited gains with additional therapy added to platinum and taxane chemotherapy backbone Screening trials continue to be unsuccessful in reducing mortality ovarian cancer phase III trials* GOG111 1 GOG ICON5/ GOG182 3 GOG158 4 GOG172 5 OVO 10 6 JGOG NOVEL 7 ICON7 8 GOG178 9 Poorer prognosis Stage IV Stage III (subopt) Stage III (optimal, macro) Stage III (optimal, micro) Stage II Stage I Stage IV, CCR Stage III CCR Better prognosis Siegel R et al. CA Cancer J Clin, 2015 Morgan et al. J Natl Compr Canc Netw *Based on data available from publications CCR = complete clinical response 1. McGuire et al. NEJM 1996; 2. Burger et al. ASCO 2010; 3. Bookman et al. JCO Ozols et al. JCO 2003; 5. Armstrong et al. NEJM 2006; 6. Piccart et al. JNCI Katsumata et al. Lancet 2009; 8. Perren et al. ESMO Markman et al. Gynecol Oncol
3 Front line trials in ovarian cancer Absolute difference in Hazard ratio Median PFS, months median PFS, months (p-value) GOG (p<0.001) GOG (p<0.001) incl CA125 GOG (p<0.001) excl CA125 ICON5/ GOG 182 (p= ) 0239) GOG NR GOG (p=0.05) OVO JGOG NOVEL (p=0.0015) ICON (p=0.0041) GOG (p=0.004) NR = not reported PLCO Effect of Screening on Ovarian Cancer Mortality* Randomized Controlled Trial And N= 78,216; N= 10 Screening Centers Usual Care (n=39,111) Annual Screening (N=39,105) Annual Screening: CA 125 x 6 years and U/S x 4 years Maximal total follow up: 13 years; median 12.4 years (Range ) *Buys et al. JAMA, 2011 PLCO Effect of Screening on Ovarian Cancer Mortality* Diagnosed Ovarian Cancers: 212 Annual Screening (5.7/10,000 person years) 176 Usual Care (4.7/10,000 person years) Ovarian Cancers Deaths: 118 Annual Screening (3.1/10,000 person years) 100 Usual Care (2.6/10,000 person years) Mortality RR 1.18 (95% CI ) intervention 3285 FP results; 1080 surgeries with 15% least 1 serious complication *Buys et al. JAMA,
4 I thought it was the Ovary? Dogma: Ovulation caused most EOC Once discovered, BRCA mutation carriers were targeted for prophylactic surgery Ultimate cancer risk reduction still requires prophylactic mastectomy RRSO gold standard for prophylaxis Although ovarian and breast cancer are decreased, patients certainly experience an impact on quality of life in terms of loss of hormonal function. Is there another option? Fathalla Lancet 1972 Kauff ND et al. N Engl J Med 2002 Schrag et al. JAMA Why excise the fallopian tube? More recently, molecular evidence suggests the fimbria may in fact may be the cause of EOC Presence of serous tubal intraepithelial cells (STIC) harbor p53 mutations and association with non hereditary Serous ovarian cancer BRCA mutation discovery and recommendations for prophylactic BSO Occult fallopian tube cancers 30% Przybycin et al. Am J Surg Pathol, 2010 Kindelberger. et al. Am J Surg Pathol Ahmed AA et al. J Pathol, 2010 Salpingectomy rather than Ligation? Tubal ligation remains a common form of contraception Salpingectomy is generally feasible and safe at the time of either cesarean delivery or LSC Salpingectomy may avoid ovarian removal or at least delay ovarian removal until closer to menopause When compare to RRSO more cost effective with improve QOL at cost of more cancers Kwon et al. Obstet Gynecol, 2013 McAlpine. et al. Am J Obstet Gynecol
5 Objectives Review and discuss the rationale for consideration of salpingectomy at time of hysterectomy and in place of tubal ligation Examine the evidence and support for salpingectomy as a preventative strategy Convince you that anything that Jacob Estes has to say should be ignored Histology Mutations Molecular Classification Overexpression Type I Low Grade Serous Mucinous Clear Cell Endometrioid Low Malignant Potential KRAS, BRAF, PTEN, ARID1A Type II High Grade Serous = High Grade Endometrioid? P53, BRCA loss HLA-G, HER2, AKT Normal Fallopian Tube Normal Ovary Ovulation, PATHWAY I PATHWAY III DNA damage, PATHWAY II P53 mutation Mullerian inclusion P53 Signature K-RAS and B-RAF Endometriosis implant or mutations Transfrormation into endometrioid epithelium Serous Intraepithelial Carcinoma Low Grade Clear cell Serous Carcinoma Carcinoma Metastatic Serous Carcinoma Endometrioid Mucinous Carcinoma Carcinoma Fallopian origin of high grade serous cancer Endometrial tissue implants lead to endometrioid and clear cell cancer Presentation Associated with Endometriosis Advanced Stage 5
6 Can we prevent ovarian cancer with any tubal surgery? Salpingectomy lowers cancer risk by 34% BRCA mutations account for 10 20% of EOC Generally high grade serous and treated with RRSO Endometrioid and clear cell cancers may be 2 to retrograde menstruation that tubal ligation prevents Pooled data: Tubal ligation risk for all EOC, although endometrioid and clear cell tumors have the greatest risk reduction Cibula et al. Human Reprod Update, 2011 Shieh. et al. Int J Epidemiol Why should I consider salpingectomy? RRSO for BRCA mutation carriers Increasingly identifying pts prior to cancer Dx Tubal ligation probably good enough for mucinous and clear cell However, non BRCA serous histology remains the most common type of EOC Almost all with p53 mutations STICs identified in the tubes with high levels of p53 mutations Can we prevent these with salpingectomy? Ahmed et al. J Pathol, 2010 Shieh. et al. Int J Epidemiol STIC Tubal intraepithelial carcinoma Tubal intraepithelial carcinoma *Erickson et al. AJOG,
7 Objectives Review and discuss the rationale for consideration of salpingectomy at time of hysterectomy and in place of tubal ligation Examine the evidence and support for salpingectomy as a preventative strategy Convince you that anything that Jacob Estes has to say should be ignored Jacob Estes Fact Made fun of me and my football team Fact Told you that there is no RCT data Fact Forgets that screening strategies do not work in ovarian cancer Fact Although just a cost effectiveness model, salpingectomy followed by bilateral oophorectomy may be a reasonable consideration. Do we really need a RCT While an RCT is preferred, is it feasible and always required? No RCTs that demonstrate the benefit of optimal cytoreduction in ovarian cancer No RCTs for benefit of chemoradiation for vulvar cancer RCT demonstrating equivalence for LSC for uterine cancer with actually didn t meet predetermined statistical endpoint of <40% increase in recurrence as HR was , yet we all do LSC When is it ok to act? Walker et al. JCO,
8 Other Risks 2003 Population 1/100 Approximate risk of ovarian cancer death Summary Planned (prophylactic salpingectomy) is a safe and potentially effective technique to decrease the risk of ovarian cancer While hl a RCT is preferred, such a trial will be both extremely expensive and long. NIH funding isn t increasing anytime soon Pre operative discussions with the patient regarding this option are justified and supported by ACOG Bruce A. Harris Progress in Ob/Gyn 2015 Jacob M. Estes, MD 8
9 Disclosures I have no financial disclosures or conflicts. Consider the Source Citadel grad, HUGE Gamecock fan Loves selfies Interestingly, he is the PI for our cooperative group trials Always wants the data RCT Unnecessary? Dr. Leath is admired for his ability to recall important GOG trials by protocol number And by date of publication And by journal And by author It s just curious that Ray would dismiss RCT s as unnecessary 9
10 Objectives Define prevent Shed light on the true pathologic data that exists Ensure that we are doing what we claim to be doing. Prevent Prevent - keep (something) from happening or arising. also defensive strategy employed by South Carolina s secondary throughout last football season Why Salpingectomy? Metaanalysis showed BTL decreased development of serous and endometrioid tumors by 34% STIC lesions in FT specimens of ovarian cancer patients exhibited identical TP53 mutations Suggested precursor lesion in fimbriated portion of tube FT is worthless in post-menopausal patients BSO associated with known harmful effects Cibula D et al. Hum Reprod Update 2011; 17:55-6 Erickson et al AJOG
11 But All cancers are not high-grade serous STIC only seen in 75% of patients with HG serous tumors Suggests ovary as origin of disease in remaining 25% All patients are not post-menopausal Impossible to perform an MTR when no tube is present We aren t preventing anything Risk of PPC remains providing false sense of security Data GOG 199 Women 30 or older at HR of developing ovarian/tubal/pp cancer BRCA positive or strong family history Patients t given the option for intense screening versus RRSO 2605 patients enrolled Pathologic data available for BRCA positive 11
12 GOG patients had path specimens that met criteria for inclusion Hmmm More Data 25 cancers detected t d (2.6%) 1.2% premenopausal 4.5% postmenopausal Only 2 cancers in 403 noncarriers 15/25 patients (60%) had lesions in the ovary or peritoneum, not the fallopian tube 12
13 Swedish Population-based Study Largest study to date Used health care registration data Examined 2 cohorts between , 465 women who underwent sterilization, hysterectomy, salpingectomy, or hysterectomy and BSO 5,449,119 in unexposed group Looked at subsequent diagnoses of ovarian or PPC HR and Incidence of Cancer by Surgery Conclusions Hysterectomy alone decreased the risk of ovarian cancer BTL and salpingectomy were equivalent with HR of.72 and.65 respectively The addition of BSO dramatically reduced the risk by 94% (HR.06) Consistent with prior smaller scale studies 13
14 Salpingectomy Does decrease the liklihood of cancer No more than BTL Where does this leave us? ACOG Committee Opinion #620, January 2015 Let s Be Cautious Questions laparoscopy as a therapeutic surgical platform Doesn t PREVENT ovarian cancer Elephant in the room is breast cancer prevention Let s just make sure we are counseling women appropriately Discuss salpingectomy during hysterectomy in women at population risk LSC salpingectomy is a good sterilization option Salpingectomy may offer surgeons a way to prevent ovarian cancer RCT needed to support these recommendations Describes it as experimental Too costly Without benefit Need RCT to support LSC 14
15 The Opinion of Those at Risk Gyn Onc 136 (2015) 305 Authors Take 4 focus group interviews with 39 BRCA carriers as well as interviews of 23 experts in hereditary cancer Barriers to salpingectomy in BRCA group Ovarian cancer, FH, previous breast cancer Barriers in expert group Delay of RR effect of oophorectomy on breast cancer risk and need for later second operation Conclusions Salpingectomy is easy to perform and has a low morbidity BUT, let s make sure we are clear that it does NOT prevent ovarian cancer Ok to counsel patients that it reduces risk of some, but not all, ovarian cancers Identification of patients at highest risk remains a priority, and those patients have definite hesitation related to salpingectomy alone 15
16 Questions 16
Inherited Ovarian Cancer Diagnosis and Prevention
Inherited Ovarian Cancer Diagnosis and Prevention Dr. Jacob Korach - Deputy director Gynecologic Oncology (past chair - Israeli Society of Gynecologic Oncology) Prof. Eitan Friedman - Head, Oncogenetics
More informationBSO, HRT, and ERT. No relevant financial disclosures
BSO, HRT, and ERT Jubilee Brown, MD Professor & Associate Director, Gynecologic Oncology Levine Cancer Institute at the Carolinas HealthCare System Charlotte, North Carolina No relevant financial disclosures
More informationCurrent Concept in Ovarian Carcinoma: Pathology Perspectives
Current Concept in Ovarian Carcinoma: Pathology Perspectives Rouba Ali-Fehmi, MD Professor of Pathology The Karmanos Cancer Institute, Wayne State University School of Medicine Current Concept in Ovarian
More informationOVARIAN CANCER Updates in Screening, Early Detection and Prevention
UW MEDICINE SUSAN PATRICIA TECK MEMORIAL LECTURE October 2017 OVARIAN CANCER Updates in Screening, Early Detection and Prevention BARBARA GOFF, MD Seattle Gynecologic Society March 2018 OVARIAN CANCER
More informationEpithelial Ovarian Cancer 8/2/2013. Tu-be or Not Tu-be: Is the Fallopian Tube the Source of Ovarian Cancer?
Tu-be or Not Tu-be: Is the Fallopian Tube the Source of Ovarian Cancer? Ann E. Smith Sehdev, MD Director, Center for Gynecologic Pathology Cascade Pathology, Portland, Oregon Ann E. Smith Sehdev has no
More informationInterpretation of p53 Immunostains. P53 Mutations are Ubiquitous in High Grade Serous Carcinoma. Diffuse strong positive nuclear staining
Stains for Tumor Classification p53 p16 WT1 HMGA2 P53 Mutations are Ubiquitous in High Grade Serous Carcinoma Source Ahmed et al Australian Ovarian Cancer Study Cancer Genome Atlas Research Network Cases
More informationBiology Response Controversies and Advances
Biology Response Controversies and Advances in BRCA related ovarian cancer Lessons learned and future directions Michael Friedlander The Prince of Wales Hospital and Royal Hospital for Women Sydney BREAST-CANCER
More informationACRIN Gynecologic Committee
ACRIN Gynecologic Committee Fall Meeting 2010 ACRIN Abdominal Committee Biomarkers & Endpoints in Ovarian Cancer Trials Robert L. Coleman, MD Professor and Vice Chair, Clinical Research Department of Gynecologic
More informationGynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure:
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationGynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Controversies in Women s Health Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationOvarian, Peritoneal, and Fallopian Tube Epithelial Cancer (OPT)
Ovarian, Peritoneal, and Fallopian Tube Epithelial Cancer (OPT) ACOG District II 2 Learning Objectives At the end of this clinical presentation, obstetrician gynecologists and other women s health care
More informationInherited Breast and Ovarian Cancer: 20 Years of Progress and Future Directions
Inherited Breast and Ovarian Cancer: 20 Years of Progress and Future Directions Noah D. Kauff, MD, FACOG Director, Clinical Cancer Genetics Duke Cancer Institute / Duke University Health System Disclosures
More informationKey Recommendations. Gynecologic management of women with inherited risk of gynecologic cancer
Gynecologic management of women with inherited risk of gynecologic cancer C. Bethan Powell MD Kaiser Permanente Northern California Gynecologic Oncology Program Lead, Kaiser Permanente Northern California
More informationCurrent state of upfront treatment for newly diagnosed advanced ovarian cancer
Current state of upfront treatment for newly diagnosed advanced ovarian cancer Ursula Matulonis, M.D. Associate Professor of Medicine, HMS Program Leader, Medical Gyn Oncology Dana-Farber Cancer Institute
More informationCancer arising from Endometriosis and Its Clinical implications
Cancer arising from Endometriosis and Its Clinical implications 1) Nezhat F, Cohen C, Rahaman J, Gretz H, Cole P, Kalir T. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign
More informationCase 1. Pathology of gynecological cancer. What do we need to know (Case 1) Luca Mazzucchelli Istituto cantonale di patologia Locarno
Case 1 Pathology of gynecological cancer. What do we need to know (Case 1) Luca Mazzucchelli Istituto cantonale di patologia Locarno SAMO Interdisciplinary Workshop on Gynecological Tumors Lucern, October
More informationOpportunistic Risk Reduction Salpingectomy and Ovarian Cancer
Opportunistic Risk Reduction Salpingectomy and Ovarian Cancer G. Kevin Donovan, MD, MA Kevin FitzGerald, SJ, Ph.D., Ph.D. Daniel Sulmasy, MD, Ph.D. Ovarian cancer has the highest mortality rate of all
More informationDisclosures/Conflict of Interest. Learning Objectives 10/2/2015. Opportunistic salpingectomy for ovarian cancer prevention Jessica N McAlpine, UBC
Opportunistic salpingectomy for ovarian cancer prevention Jessica N McAlpine, UBC Disclosures/Conflict of Interest No conflicts of interest to declare No discussion re off label use and/or investigational
More informationPartners: Introductions: Dr. Carolyn Johnston Deanna Cosens & Ann Garvin. Ovarian Cancer and Primary Care July 16, :00 9:00am EST 7/16/2014
Welcome To The Webinar Technical Support Ovarian Cancer and Primary Care July 16, 2014 8:00 9:00am EST In order to hear the presentation please call 1 (626) 544-0058, access code 167-314-644, followed
More informationOvarian cancer: 2012 Update Srini Prasad MD Univ Texas MD Anderson Cancer Center
Ovarian cancer: 2012 Update Srini Prasad MD Univ Texas MD Anderson Cancer Center Ovarian cancer is not a single disease Ovarian Epithelial Tumors: Histological Spectrum* Type Frequency Histology High-Grade
More informationIs It Time To Implement Ovarian Cancer Screening?
Is It Time To Implement Ovarian Cancer Screening? Prof Dr Samet Topuz Istanbul Medıcal Faculty Department Of Obstetrics and Gynecology ESGO Prevention in Gynaecological Malignancies September 08 2016 Antalya
More informationKey Recommendations. Gynecologic management of women with inherited risk of gynecologic cancer. HBOC related genes. I have nothing to disclose
Gynecologic management of women with inherited risk of gynecologic cancer C. Bethan Powell MD Kaiser Permanente Northern California Gynecologic Oncology Program I have nothing to disclose Key Recommendations
More informationBoth type I and type II tumors develop from extraovarian tissue that implants on the ovary. Both for LGSC and HGSC, the fallopian tube appears to be
Recent studies have led to the development of a new paradigm for the pathogenesis and origin of EOC, based on a dualistic model of carcinogenesis that divides EOC into 2 broad categories designated types
More informationBases biológicas del cáncer de ovario en el siglo XXI
Bases biológicas del cáncer de ovario en el siglo XXI Iñigo Espinosa, M.D. Clínica Universidad de Navarra Epithelial Ovarian Tumors WHO 1973-2014 Serous Mucinous Endometrioid Clear cell Transitional Squamous
More informationJemal A, Siegel R, Ward E, et al: Cancer statistics, CA: Cancer J Clin 59(4):225-49, 2009
Ovarian cancer 2010-22,500 cases diagnosed per year in the United States and 16,500 deaths per year1. - Most patients are diagnosed in late stages; no screening test exists. - Pathology: 4 different types
More informationLessons learned for the conduct of a successful screening trial
Lessons learned for the conduct of a successful screening trial Christine D. Berg, M.D. Adjunct Professor Department of Radiation Oncology Johns Hopkins Medicine IOM State of the Science in Ovarian Cancer
More informationSCREENING FOR OVARIAN CANCER DR MACİT ARVAS
SCREENING FOR OVARIAN CANCER DR MACİT ARVAS Ovarian cancer is the leading cause of death from gynecologic malignancy In 2008, ovarian cancer was the seventh common cancer in women worldwide There were
More informationFoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV
FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common
More informationRisk Reduction management for Ovarian Cancer in Women with BRCA1/2 Mutation
Risk Reduction management for Ovarian Cancer in Women with BRCA1/2 Mutation Global Breast Cancer Conference 2018 2018. 4. 6 (Fri) Songdo, Incheon, Korea Hereditary Gynecologic Cancer Clinic Precision Medicine
More informationChristine Herde, MD, FACOG
Christine Herde, MD, FACOG Vice Chair, Department of OB/GYN CareMount Medical, Mount Kisco, NY Assistant Director of OB/GYN, Mount Sinai Health System at CareMount Medical 1. OSE presumption that Ovarian
More informationOvarian Cancer Causes, Risk Factors, and Prevention
Ovarian Cancer Causes, Risk Factors, and Prevention Risk Factors A risk factor is anything that affects your chance of getting a disease such as cancer. Learn more about the risk factors for ovarian cancer.
More informationBackground. Background. Background. Background 2/2/2015. Endometriosis-Associated Ovarian Cancer: Malignant Transformation of Endometriosis
Endometriosis-Associated Ovarian Cancer: Malignant Transformation of Endometriosis I have no disclosures. Marcela G. del Carmen, MD, MPH Associate Professor Division of Gynecologic Oncology EOC is gynecologic
More informationUpdate on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact
Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact Bjørn Hagen, MD, PhD St Olavs Hospital Trondheim University Hospital Trondheim, Norway Endometrial Cancer (EC) The most
More information--- or not, and do we need to come up with newer strategies for ovarian cancer screening.
My name is Dr. Karen Lu and I am a Professor of Gynecologic Oncology at the University of Texas MD Anderson Cancer Center. I also serve as Co-Medical Director for Clinical Cancer Genetics. I m going to
More information6 Week Course Agenda. Today s Agenda. Ovarian Cancer: Risk Factors. Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention
6 Week Course Agenda Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention Lee-may Chen, MD Director, Division of Gynecologic Oncology Professor Department of Obstetrics, Gynecology
More informationManagement of BRCA mutation carriers
Management of BRCA mutation carriers Clinical Case Presentation Shani Paluch-Shimon, MBBS, MSc Head, Breast Cancer Service for Young Women Oncology Institute Sheba Medical Center, Israel esmo.org DISCLOSURES
More informationSo how much of breast and ovarian cancer is hereditary? A). 5 to 10 percent. B). 20 to 30 percent. C). 50 percent. Or D). 65 to 70 percent.
Welcome. My name is Amanda Brandt. I am one of the Cancer Genetic Counselors at the University of Texas MD Anderson Cancer Center. Today, we are going to be discussing how to identify patients at high
More informationSurgery to Reduce the Risk of Ovarian Cancer. Information for Women at Increased Risk
Surgery to Reduce the Risk of Ovarian Cancer Information for Women at Increased Risk Centre for Genetics Education NSW Health 2017 The Centre for Genetics Education NSW Health Level 5 2C Herbert St St
More informationHistopathological Study of Spectrum of Lesions Seen in Surgically Resected Specimens of Fallopian Tube
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2016/613 Histopathological Study of Spectrum of Lesions Seen in Surgically Resected Specimens of Fallopian Tube Pratima
More informationScreening and prevention of ovarian cancer
Chapter 2 Screening and prevention of ovarian cancer Prevention of ovarian carcinoma Oral contraceptive pills Use of oral contraceptive pills (OCPs) has been associated with a significant reduction in
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): October 1, 2014 Most Recent Review Date (Revised): May 20, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More information3 cell types in the normal ovary
Ovarian tumors 3 cell types in the normal ovary Surface (coelomic epithelium) the origin of the great majority of ovarian tumors (neoplasms) 90% of malignant ovarian tumors Totipotent germ cells Sex cord-stromal
More information4:00 into mp3 file Huang_342831_5_v1.mp3
Support for Yale Cancer Answers comes from AstraZeneca, providing important treatment options for women living with advanced ovarian cancer. Learn more at astrazeneca-us.com. Welcome to Yale Cancer Answers
More informationLong-Term Health Outcomes of Surgical Menopause
Long-Term Health Outcomes of Surgical Menopause Vanessa Jacoby, MD, MAS Associate Professor Obstetrics, Gynecology, and Reproductive Sciences University of California, San Francisco None Disclosures Overview
More informationHereditary Breast and Ovarian Cancer Rebecca Sutphen, MD, FACMG
Hereditary Breast and Ovarian Cancer 2015 Rebecca Sutphen, MD, FACMG Among a consecutive series of 11,159 women requesting BRCA testing over one year, 3874 responded to a mailed survey. Most respondents
More information8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview
Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay
More informationEDUCATIONAL COMMENTARY CA 125. Learning Outcomes
EDUCATIONAL COMMENTARY CA 125 Learning Outcomes Upon completion of this exercise, participants will be able to: discuss the use of CA 125 levels in monitoring patients undergoing treatment for ovarian
More informationJoshua Cohen MD Gynecologic Oncology Fellow UCLA/Cedars-Sinai Medical Center
Joshua Cohen MD Gynecologic Oncology Fellow UCLA/Cedars-Sinai Medical Center No conflicts of interest to disclose Educational Objectives Recognize challenges in current paradigms associated with biomarker
More informationHereditary Gynecologic Cancer 15 Years of Progress
Hereditary Gynecologic Cancer 15 Years of Progress Bethan Powell, M. D. Kaiser Permanente UCSF Gynecologic Cancer Risk Program Hereditary Gynecologic Cancer Syndromes BRCA 1 and 2: ovarian Lynch: ovarian/endometrial
More informationGUIDE TO REVIEWING A MANUSCRIPT
GUIDE TO REVIEWING A MANUSCRIPT The First Read-Through: Overall Impression Try to bear in mind the following question: Is the main question addressed relevant and interesting? How original is the topic?
More informationTumori eredofamiliari: sorveglianza di donne ad alto rischio
Tumori eredofamiliari: sorveglianza di donne ad alto rischio 14/01/2018 Dott Matteo Generali AUSL Modena Carpi U.O. Ostetricia e Ginecologia Screening for gynaecologic cancer in genetically predisposed
More informationPolicy #: 259 Latest Review Date: November 2009
Name of Policy: Prophylactic Oophorectomy Policy #: 259 Latest Review Date: November 2009 Category: Surgery Policy Grade: Active Policy but no longer scheduled for regular literature reviews and updates.
More informationLow-grade serous neoplasia. Robert A. Soslow, MD
Low-grade serous neoplasia Robert A. Soslow, MD soslowr@mskcc.org Outline Orientation Ovarian tumor overview Non serous borderline tumors Serous borderline tumors Clinical summary Morphologic description
More informationSection 1. Biology of gynaecological cancers: our current understanding
Section 1 Biology of gynaecological cancers: our current understanding Chapter 1 Morphological sub-types of ovarian carcinoma: new developments and pathogenesis W Glenn McCluggage 1 Introduction In most
More informationACCME/Disclosures. Risk of Gyne Ca in HBOC. Molecular basis of HBOC. Hereditary Ovarian and Breast Cancer Syndrome
Hereditary Ovarian and Breast Cancer Syndrome C. Blake Gilks, MD Dept of Pathology Vancouver General Hospital University of British Columbia Blake.gilks@vch.ca The USCAP requires that anyone in a position
More informationTriage of Ovarian Masses. Andreas Obermair Brisbane
Triage of Ovarian Masses Andreas Obermair Brisbane Why Triage? In ovarian cancer, best outcomes for patients can be achieved when patients are treated in tertiary centres by a multidisciplinary team led
More informationScreening for ovarian cancer Kehoe, Sean
Screening for ovarian cancer Kehoe, Sean DOI: 10.1016/j.maturitas.2015.05.009 License: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) Document Version Peer reviewed version Citation
More informationPractice of Medicine-1 Ovarian Cancer Clinical Correlation
Practice of Medicine-1 Ovarian Cancer Clinical Correlation Amir A. Jazaeri, M.D. Assistant Professor, Division of Gynecologic Oncology American Cancer Society Female Cancers 2000 Statistics Reprinted by
More informationSerous Tubal Intraepithelial Carcinoma in a Japanese Woman with a Deleterious BRCA1 Mutation
Japanese Journal of Clinical Oncology Advance Access published April 9, 2014 Jpn J Clin Oncol 2014 doi:10.1093/jjco/hyu035 Case Report Serous Tubal Intraepithelial Carcinoma in a Japanese Woman with a
More informationOvarian Cancer. Disclosure. Ovarian Statistics Educational Objectives. The State of Ovarian Care in the US Why aren t we making more progress?
Esteemed Physician Humanitarian Distinguished Citizen Disclosure Ovarian Cancer The State of Ovarian Care in the US Why aren t we making more progress? Dr. Goff has indicated that she has no relevant financial
More informationX-Plain Ovarian Cancer Reference Summary
X-Plain Ovarian Cancer Reference Summary Introduction Ovarian cancer is fairly rare. Ovarian cancer usually occurs in women who are over 50 years old and it may sometimes be hereditary. This reference
More informationOvarian Cancer: Implications for the Pharmacist
Ovarian Cancer: Implications for the Pharmacist Megan May, Pharm.D., BCOP Objectives Describe the etiology and pathophysiology of ovarian cancer Outline the efficacy and safety of treatment options for
More informationScreening in Ovarian Cancer: Any closer to the Holy Grail?
Screening in Ovarian Cancer: Any closer to the Holy Grail? Charles Chip Landen, Jr., M.D., M.S. Associate Professor, Departments of Obstetrics and Gynecology, and Pathology Associate Leader, Women s Oncology
More informationbreast and OVARIAN cancer
breast and OVARIAN cancer DR DAVID FENNELLY CONSULTANT MEDICAL ONCOLOGIST ST VINCENT S UNIVERSITY HOSPITAL DUBLIN HOW RELEVANT IS ONCOLOGY IN MEDICINE TODAY? Cancer is the second leading cause of death
More informationFAQ-Protocol 3. BRCA mutation carrier guidelines Frequently asked questions
ULast updated: 09/02/2015 Protocol 3 BRCA mutation carrier guidelines Frequently asked questions UQ: How accurate are the remaining lifetime and 5 year breast cancer risks in the table? These figures are
More informationClinical Trials. Ovarian Cancer
1.0 0.8 0.6 0.4 0.2 0.0 < 65 years old 65 years old Events Censored Total 128 56 184 73 35 108 0 12 24 36 48 60 72 84 27-10-2012 Ovarian Cancer Stuart M. Lichtman, MD Attending Physician 65+ Clinical Geriatric
More informationUtilization of BRCA Testing. Breast and Ovarian Cancer in Texas
Utilization of BRCA Testing in Older Ode Women with Breast and Ovarian Cancer in Texas Ana M. Rodriguez, MD Assistant Professor Department of Obstetrics and Gynecology University of Texas Medical Branch
More informationWinship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer
Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer Ira R. Horowitz, MD, SM, FACOG, FACS John D. Thompson Professor and Chairman Department of Gynecology
More informationContents Introduction. Recommendations at a Glance. Introduction. Background. Clinical Recommendations
Salpingectomy for Ovarian Cancer Prevention May 2013 Contents Introduction Indications for Salpingectomy Technique Pathology Processing References, Authors, Appendix, Acknowledgements, and Disclaimer Recommendations
More informationRicombinazione omologa nel carcinoma ovarico: BRCA e oltre. F. Raspagliesi MD
Ricombinazione omologa nel carcinoma ovarico: BRCA e oltre F. Raspagliesi MD raspagliesi@istitutotumori.mi.it BRCA molecular signature in ovarian cancer In a pooled analysis of 26 observational studies
More informationOriginal Research. Background
Original Research 849 in Carboplatin and Dose-Dense Paclitaxel Chemotherapy for Ovarian Malignancies: A Survey of NCCN Member Institutions Marina Stasenko, MD a ; R. Kevin Reynolds, MD a ; Carolyn Johnston,
More informationBRCA mutation carrier patient: How to manage?
BRCA mutation carrier patient: How to manage? Clinical Case Presentation Katarzyna Sosińska-Mielcarek Department of Oncology and Radiotherapy University Clinical Center Gdansk, Poland esmo.org DISCLOSURE
More informationCase # 4 Low-Grade Serous Carcinoma (Macropapillary) of the Ovary Arising in an Atypical Proliferative Serous Tumor
Case # 4 Low-Grade Serous Carcinoma (Macropapillary) of the Ovary Arising in an Atypical Proliferative Serous Tumor Robert J Kurman, M.D. Johns Hopkins University School of Medicine Case History A 53 year
More informationof 20 to 80 and subsequently declines [2].
- - According to the 2014 World Health Organization (WHO) classification and tumor morphology, primary ovarian tumors are subdivided into three categories: epithelial (60%), germ cell (30%), and sex-cord
More informationProgress Update June 2017 Lay Summary Funding: $6,000,000 Grant Funded: July 2015 Dream Team Members Dream Team Leader:
SU2C -Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team Translational Research Grant: DNA Repair Therapies for Ovarian Cancer AND SU2C Catalyst Merck-Supported Supplemental
More informationProf. Dr. Aydın ÖZSARAN
Prof. Dr. Aydın ÖZSARAN Adenocarcinomas of the endometrium Most common gynecologic malignancy in developed countries Second most common in developing countries. Adenocarcinomas, grade 1 and 2 endometrioid
More informationPatologia Molecular del Carcinoma de Ovario
Curso de Patologia Molecular XXVI Congreso Nacional de la SEAP Cadiz Patologia Molecular del Carcinoma de Ovario Jaime Prat Barcelona Ovarian Epithelial Tumors WHO 1999 and 2003 Serous Mucinous Endometrioid
More informationMousa. Najat kayed &Renad Al-Awamleh. Nizar Alkhlaifat
6 Mousa Najat kayed &Renad Al-Awamleh Nizar Alkhlaifat P a g e 1 This sheet written based on record 13 on website Cover slide( 95-117 ) No need to go back to slide FALLOPIAN TUBE PATHOLOGY In general fallopian
More informationGenetics of Breast and Ovarian Cancer: Risk Assessment, Screening, and Risk Reduction
Genetics of Breast and Ovarian Cancer: Risk Assessment, Screening, and Risk Reduction Forum INCA-ASCO sobre Cancer Hereditario e Predisposicao Genetica ao Cancer Jeffrey N. Weitzel, M.D. Professor of Oncology
More informationMPH Quiz. 1. How many primaries are present based on this pathology report? 2. What rule is this based on?
MPH Quiz Case 1 Surgical Pathology from hysterectomy performed July 11, 2007 Final Diagnosis: Uterus, resection: Endometrioid adenocarcinoma, Grade 1 involving most of endometrium, myometrial invasion
More informationpatient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015
patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015 BRCA1 and BRCA2 Mutations Cancer is a complex disease thought to be caused by several different factors. A few types of cancer
More informationRisk-reducing Surgery in BRCA mutation carriers
Risk-reducing Surgery in BRCA mutation carriers Daerim St. Mary s Hospital Department of Surgery, Breast Care Center Hereditary Breast Ovarian Cancer Clinic Sung-Won Kim, MD, PhD, FACS Overview of HBOC
More informationThe Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology
The Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology April 26, 2013 Larry J. Copeland M.D. Thank You for Your Friendship! 1982 1996 2013 The Ohio State University
More informationPROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC
PROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC Giorgia Mangili RUF ginecologia oncologica medica IRCCS San Raffaele Milano mangili.giorgia@hsr.it STANDARD CHEMOTHERAPY The standard chemotherapy
More informationLynch Syndrome. Angie Strang, PGY2
Lynch Syndrome Angie Strang, PGY2 Background Previously hereditary nonpolyposis colorectal cancer Autosomal dominant inherited cancer susceptibility syndrome Caused by defects in the mismatch repair system
More informationRESEARCH COMMUNICATION
RESEARCH COMMUNICATION Clinicopathologic Analysis of Women with Synchronous Primary Carcinomas of the Endometrium and Ovary: 10- Year Experience from Chiang Mai University Hospital Jiraprapa Natee 1 *,
More informationChristine Garcia, MD 1, Liisa Lyon, MS 2, Ramey D. Littell, MD 1 and C. Bethan Powell, MD 1
American College of Medical Genetics and Genomics Comparison of risk management strategies between women positive for a BRCA variant of unknown significance and women with known BRCA deleterious mutations
More informationIdentification of Potential Therapeutic Targets by Molecular and Genomic Profiling of 628 Cases of Uterine Serous Carcinoma
Identification of Potential Therapeutic Targets by Molecular and Genomic Profiling of 628 Cases of Uterine Serous Carcinoma Nathaniel L Jones 1, Joanne Xiu 2, Sandeep K. Reddy 2, Ana I. Tergas 1, William
More informationUAB Ovarian Cancer Clinical Trials. Charles A. Leath, III, MD, MSPH
UAB Ovarian Cancer Clinical Trials Charles A. Leath, III, MD, MSPH Disclosures I will discuss non-fda approved indications for several medications I perform contracted research for the following companies:
More informationThe Diagnostic Challenges of Low Grade and High Grade Tubo-Ovarian Serous Carcinomas. W Glenn McCluggage Belfast, Northern Ireland
The Diagnostic Challenges of Low Grade and High Grade Tubo-Ovarian Serous Carcinomas W Glenn McCluggage Belfast, Northern Ireland Enterprise Interest None OVARIAN SEROUS CARCINOMA (OSC) RECENT DEVELOPMENTS
More informationIvyspring International Publisher. Introduction. Journal of Cancer 2018, Vol. 9. Abstract
141 Ivyspring International Publisher Research Paper Journal of Cancer 2018; 9(1): 141-147. doi: 10.7150/jca.21187 Opportunistic salpingectomy at benign gynecological surgery for reducing ovarian cancer
More informationPARP Inhibitors: Patients Selection. Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016
PARP Inhibitors: Patients Selection Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016 OVARIAN CANCER (OC): MULTIPLES DISEASES Different types with different behaviour
More informationInstitute of Pathology First Faculty of Medicine Charles University. Ovary
Ovary Barrett esophagus ph in vagina between 3.8 and 4.5 ph of stomach varies from 1-2 (hydrochloric acid) up to 4-5 BE probably results from upward migration of columnar cells from gastroesophageal junction
More information10/24/14. Grand Rounds in Ovarian Cancer: Standards of Care and Novel Treatment Approaches. Disclosure. Learning Objectives
10/24/14 Grand Rounds in Ovarian Cancer: Standards of Care and Novel Treatment Approaches Jessica Gahres, PA-C Memorial Sloan Kettering Cancer Center Don S. Dizon, MD Massachusetts General Hospital Cancer
More informationreceive adjuvant chemotherapy
Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer
More informationAdnexal Mass Management: Risk Stratification and Management Practice for Best Patient Outcomes
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationWelcome! Here s our agenda for today:
Welcome! Here s our agenda for today: What is ovarian cancer? What causes it? When does genetic testing come in? When are families at risk for ovarian cancer? What are the treatments? 3 things to remember
More informationOvarian Clear Cell Carcinoma
Ovarian Clear Cell Carcinoma Rouba Ali-Fehmi, MD Professor of Pathology The Karmanos Cancer Institute, Wayne State University School of Medicine 50 year old woman with chief complaint of shortness of breath
More information3 cell types in the normal ovary
Ovarian tumors 3 cell types in the normal ovary Surface (coelomic epithelium) the origin of the great majority of ovarian tumors 90% of malignant ovarian tumors Totipotent germ cells Sex cord-stromal cells
More informationSOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer
SOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer Charles Moertel Lecture May 12, 2017 Gini Fleming Charles Moertel Founder of NCCTG Dedication to high quality clinical
More information